Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | Garetosmab | Fibrodysplasia ossificans progressiva (FOP) | Phase 2 | Trial Discontinued | Intravenous | Genetic Disorder |
| Regeneron Pharmaceuticals Inc. | Pozelimab (REGN3918) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 2 | Ongoing | Intravenous | Hematology |
| Regeneron Pharmaceuticals Inc. | SAR4442454, BNT111 and LIBTAYO (cemiplimab) | Melanoma | Phase 2 | Data Released | SAR4442454: Intravenous BNT111: Intravenous LIBTAYO (cemiplimab): Intravenous | Oncology |
| REGENXBIO Inc. | Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE) | Wet AMD | Phase 2/3 | Enrollment Conclusion | Subretinal injection | Opthalmic |
| REGENXBIO Inc. | Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ASCENT) | Wet age-related macular degeneration (wet AMD) | Phase 2 | Data Released | Subretinal injection | Opthalmic |
| REGENXBIO Inc. | RGX-314 | Neovascular Age-related macular degeneration (AMD) | Phase 2 | Data Released | Subretinal or suprachoroidal injection | Opthalmic |
| REGENXBIO Inc. | RGX-314 - (AAVIATE) | Wet AMD using suprachoroidal delivery | Phase 2 | Data Released | Intravitreal injection | Opthalmic |
| REGENXBIO Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | Phase 2 | Data Released | Suprachoroidal injection | Opthalmic |
